Insulet Co. (NASDAQ:PODD) EVP Eric Benjamin Sells 12,394 Shares

by · The Markets Daily

Insulet Co. (NASDAQ:PODD – Get Free Report) EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Insulet Trading Up 1.0 %

Shares of NASDAQ PODD traded up $2.81 during mid-day trading on Wednesday, hitting $278.89. The stock had a trading volume of 555,597 shares, compared to its average volume of 536,507. The firm has a market cap of $19.56 billion, a P/E ratio of 47.76, a price-to-earnings-growth ratio of 3.46 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The business has a 50 day moving average price of $266.32 and a two-hundred day moving average price of $234.07. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $282.86.

Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same period in the prior year, the firm posted $0.71 earnings per share. On average, equities analysts anticipate that Insulet Co. will post 3.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on PODD. Canaccord Genuity Group upped their target price on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Wells Fargo & Company upped their target price on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, Citigroup upped their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $272.81.

Get Our Latest Stock Analysis on PODD

Institutional Investors Weigh In On Insulet

Institutional investors and hedge funds have recently bought and sold shares of the business. Blue Trust Inc. increased its position in shares of Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC raised its position in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the period. Friedenthal Financial bought a new stake in shares of Insulet during the fourth quarter valued at approximately $57,000. Finally, Versant Capital Management Inc grew its stake in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 157 shares during the period.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Recommended Stories